Skip to main content
Vaccine: X logoLink to Vaccine: X
. 2022 Oct 17;12:100227. doi: 10.1016/j.jvacx.2022.100227

Pharmacy deserts and COVID-19 risk at the census tract level in the State of Washington

Rachel Wittenauer a,, Parth D Shah b, Jennifer L Bacci a, Andy Stergachis a,c
PMCID: PMC9574851  PMID: 36275889

Highlights

  • Pharmacy desert communities have worse access to key services like vaccination.

  • In Washington State, over 450,000 adults (8% of adults) live in pharmacy deserts.

  • Those living in pharmacy deserts were also associated with higher risk for COVID-19.

  • Several policy solutions are needed to address the access gap for pharmacy services.

Keywords: Vaccine distribution, Pharmacy, Vaccine access, Pandemic preparedness

Abstract

Community pharmacies are a crucial component of healthcare infrastructure, including for COVID-19 pandemic prevention services like testing and vaccination. Communities that are “pharmacy deserts,” experience healthcare inequities. However, little research has characterized where these communities are, making it difficult for local leaders to prioritize resources for them. This study identifies pharmacy deserts at the census tract level in Washington state for the first time and explores their association with COVID-19 risk. Out of 1,441 tracts, 127 were pharmacy deserts, comprising approximately 454,000 adults, or 8% of the state’s adult population. Among those tracts identified as pharmacy deserts, 67% were considered high risk for COVID-19. Solutions are needed to expand equitable access to pharmacy services in these communities. The methods and data presented herein provide healthcare leaders with information to address this pharmacy access gap in Washington and could be similarly applied to other settings. Three categories of policy changes could address health inequities found in our study: 1) improve financial incentives for pharmacists to practice in underserved areas, 2) prevent pharmacy closures, and 3) deploy innovative care delivery methods such as telehealth services.

Introduction

The COVID-19 pandemic has revealed inequities in access to healthcare in the United States (US), and the importance of establishing a robust healthcare and public health preparedness system. Community pharmacies are an integral component of the US healthcare infrastructure and are the most widely dispersed healthcare access point in the US. Nationally, about 89 % of adults live within 5 miles of a pharmacy [1]. Pharmacies provide a wide range of patient care services, such as vaccinations, point-of-care testing, and dispensing of medications, including public health emergency countermeasures. To standardize variation in state laws and ease national vaccine implementation during COVID-19 pandemic, the Department of Health and Human Services (HHS) issued nationwide guidance granting pharmacists, student pharmacists, and pharmacy technicians the authority to order and administer COVID-19 vaccinations [2], [3]. Leveraging community pharmacies as immunization access points relieves care burden for other healthcare providers and increases access to preventive care services for medically underserved populations [4]. As with the 2009 H1N1 influenza A pandemic response, community pharmacists are again playing key roles as immunizers on the front lines of a public health emergency [5], [6].

Despite pharmacy’s importance in patient care services and better geographic distribution compared to other healthcare provider types, many individuals still face barriers to accessing pharmacies and pharmacist-provided services depending on where they live. Communities which are both low-income and have low geographic access to pharmacies are known as “pharmacy deserts” [7]. Pharmacy deserts have seen increased attention and study during the COVID-19 pandemic because of their implications for poor access to testing and vaccinations [4], [8], [9]. In addition to COVID-19 related services, pharmacy deserts have important health implications in that proximity to pharmacies and pharmacy closures have been shown to negatively impact adherence to medications for chronic illnesses and receipt of influenza vaccination among breast cancer patients [10], [11], [12]. Further, not all communities are impacted equally by pharmacy closures, as a higher proportion of pharmacy closures are in non-white, lower-income neighborhoods [10].

Evidence is growing on the locations and characteristics of pharmacy deserts and pharmacy access in the US. These communities have been identified at the census tract or ZIP code level in certain geographies including Los Angeles County, Chicago metro area, the state of Pennsylvania, New York City, Shelby County Tennessee, in the thirty largest metropolitan areas of the United States, and at the county level for selected rural counties [7], [13], [14], [15], [16], [17], [18], [19]. These studies have also identified several social determinants of health and demographic characteristics associated with the prevalence of pharmacy deserts, including denser population, higher proportion of renters, more residents that speak English as a second language, more residents living under the federal poverty level, higher proportion of Black and Hispanic residents, and fewer health professionals who serve the area [14], [17], [18].

Gaps remain in the literature of both the geography and characteristics of pharmacy deserts. Pharmacy deserts have only been identified at the census tract level for few geographic regions. Further, no analyses have examined the relationship between pharmacy deserts and COVID-19 risk, which is important for efficient allocation of limited resources to response and recovery from COVID-19 and future pandemics. The objectives of this study were to identify communities designated as pharmacy deserts in Washington state (WA) and examine the relationship between pharmacy deserts and community COVID-19 risk. By achieving these objectives, we provide information that enables prioritization of resources for communities with greater risks and inequities associated with poor pharmacy access.

Methods

Data collection and sources

Pharmacy data source. Data were collected from four existing publicly available sources. The names and addresses of pharmacies with active licenses during 2020 were provided by the Washington State Pharmacy Association. We identified a total of 1,877 active pharmacy licenses. We then excluded pharmacies that were: 1) healthcare entities, or organizations that provide healthcare services in a setting that is not otherwise licensed by the state to purchase and possess legend drugs such as outpatient surgery centers and residential treatment facilities; 2) hospital pharmacy-associated clinics, or an individual practitioner's office; or 3) hospital pharmacies. After these exclusions, a total of 1,330 community pharmacies were included in our analytic sample. These addresses were geocoded for analysis using the GoogleMaps application programming interface (API).

Census data source. Data were obtained at the census tract-level for population characteristics of median income, percent of individuals living below the federal poverty level, vehicle ownership, age, and population estimates from the 2019 5-year American Community Survey (ACS) [20]. Rural-Urban Commuter Area (RUCA) codes from the Washington State Department of Health (WADOH) were used to classify each tract as urban or rural [21].

COVID-19 risk score data source. COVID-19 vulnerability was defined using the COVID-19 Community Vulnerability Index (CCVI). The CCVI is based on the widely-used US Centers for Disease Control and Prevention’s Social Vulnerability Index (SVI), which is based on 4 themes: socioeconomic status, household composition and disability, minority status and language, and housing type & transportation [22], [23], [24]. The CCVI then adds two more COVID-19 specific risk themes to those 4: 5) epidemiological factors such as population density and prevalence of diabetes and 6) healthcare system factors such as health system capacity and AHRQ Prevention Quality Indicator Overall Composite Score, for a total of 6 risk areas by census tract and then organized into quintiles [23]. The CDC is relying on the SVI for vaccine planning nationally, but the CCVI was chosen for this analysis because it aligned with WADOH planning efforts and includes timely COVID-19 specific measures of risk. The use of COVID-19 case data rather than a risk index in this analysis was 1) not possible due to lack of case count data availability at the census tract level, and 2) subject to limitations of its own such as the highly varied phases of the pandemic and wide distribution of vaccines in non-pharmacy settings. Instead, the CCVI provides a uniform measure of community risk which, while not directly tied to COVID-19 case counts, allows us to identify gaps between anticipated community health needs and available pharmacy services.

There are 1,454 census tracts in Washington, of which we were able to analyze 1,441 (99.1 %). Thirteen tracts were excluded because they either had a population of zero or were suppressed for having too few residents to publicly report a median income. Results were organized by local health jurisdictions (LHJs), which are the local-level health authorities in the state. Washington has 31 county health departments, three multi-county health districts and two city-county health departments, which are collectively referred to as LHJs [25].

Outcome measures

This analysis had two outcome measures of interest to define the location of underserved communities. As our primary outcome, we identified the prevalence of pharmacy deserts at the tract level and examined which of those tracts were also at high COVID-19 risk. Second, we identified the expected capacity of pharmacies located in each census tract, as defined by the number of adults per pharmacy residing in each community.

Pharmacy deserts

A pharmacy desert is defined as a community (census tract) which is both “low-income” and has “low access” geographically to pharmacies. This definition is widely used in other pharmacy deserts studies [7], [26], [27] and is based on the Centers for Disease Control and Prevention’s and US Department of Agriculture (USDA)’s definition of a food desert, which is a similar concept in terms of neighborhood access to resources for health [28], [29]. This analysis applied the same definitions for these variables as described by Qato et al [7]. Specifically, “low-income” is defined as tracts where the median household income is less than 80 % of the income of the nearest metropolitan area, or where more than 20 % of residents have a household income below the federal poverty line. “Low access” is defined as where more than one-third of a census tract’s population is living farther than 1 mile from the nearest pharmacy (1 mile for urban tracts, 10 miles for rural tracts, and 0.5 miles for low-vehicle-access tracts). A low vehicle access tract is one where more than 100 households do not own a vehicle. This proportion was calculated by identifying if the centroid of a census block group was located within the specified radius of a pharmacy, and if so, then considering the population of that block to be “near” a pharmacy, then dividing the population near a pharmacy over the total population of that census tract. With this approach, we were able to define populations based on proximity to pharmacies even if a specific pharmacy was not within the border of the census tract. Urban and rural status was defined using RUCA codes from WADOH [21]. Prevalence of pharmacy deserts in urban versus rural census tracts were also examined.

Pharmacies per capita

In addition to pharmacy deserts, as a secondary outcome we characterized the expected catchment population of each pharmacy, which we defined as pharmacies per adult population per census tract. The threshold for a federally-designated Health Professional Shortage Area (HPSA) is a population to provider ratio of 3,500 or more. We used this threshold to identify areas in which pharmacies are serving a catchment area with a larger population than 3,500 people [30]. There are more pharmacy locations than primary care locations in the US (supporting a smaller catchment ratio), though patients visit pharmacies more frequently than their primary care physicians [31] (supporting a larger catchment ratio), thus the 1 per 3,500 ratio is potentially not as applicable to pharmacies as it is for primary care. However, an average catchment area size for pharmacies has yet to be defined and broadly adopted in pharmacy access literature, and so 1 per 3,500 is used for comparison purposes.

Statistical analyses

We identified pharmacy deserts geographically and visually displayed them on a choropleth map along with COVID-19 risk. We used chi-squared tests to evaluate statistically significant differences in the 1) proportion of adults and 2) population living in pharmacy deserts by LHJ. We assessed statistical significance of mean number of pharmacies per tract in each LHJ using univariate logistic regression. We reported frequencies of pharmacy deserts by risk status in the CCVI. All analyses were performed using R Studio.

Results

Pharmacy deserts

Out of the 1,441 census tracts analyzed, 127 tracts were identified as pharmacy deserts. Approximately 454,000 adults lived in pharmacy deserts, or about 8 % of Washington State’s adult population. The LHJs with the highest proportion of adults living in pharmacy deserts were Okanogan County Public Health (42 %), Klickitat County Public Health (21 %), and Benton-Franklin Health District (12 %). The LHJs with the highest number of adults living in pharmacy deserts were Seattle and King County Public Health (153,711 adults), Tacoma-Pierce County Health Department (66,844 adults), and Snohomish Health District (36,339 adults). These LHJs are the health authorities of the three most populous counties in Washington State, all surrounding the Seattle-Tacoma metropolitan area. Thirteen of the 35 LHJs had no adults living in pharmacy deserts. The variation between LHJs of number of adults and proportion of adults living in pharmacy deserts was not statistically significant (p = 0.28). These results are summarized in Exhibit 1.

Exhibit 1.

Adult population living in pharmacy deserts by local health jurisdiction.

Adults Living in Pharmacy Deserts1 Percent of Adults Living in Pharmacy Deserts2 Proportion of All Tracts in LHJ which are Pharmacy Deserts
Local Health Jurisdiction
King 153,711 8.80 % 9.57 %
Pierce 66,844 9.99 % 11.70 %
Snohomish 36,339 5.89 % 6.71 %
Spokane 26,728 6.80 % 6.67 %
Benton-Franklin 24,186 11.71 % 12.50 %
Clark 23,079 6.44 % 6.73 %
Kitsap 19,146 9.20 % 7.55 %
Thurston 17,587 8.02 % 8.16 %
Yakima 15,350 8.75 % 11.11 %
Whatcom 14,288 8.05 % 8.82 %
Okanogan 13,360 41.46 % 40.00 %
Skagit 10,200 10.41 % 10.34 %
Cowlitz 8,109 9.85 % 16.67 %
Northeast Tri County 5,720 10.96 % 15.00 %
Chelan-Douglas 4,547 5.10 % 4.55 %
Lewis 4,438 7.24 % 10.00 %
Klickitat 3,732 21.33 % 33.33 %
Grant 2,557 3.80 % 6.25 %
Asotin 1,925 10.79 % 16.67 %
Clallam 1,049 1.68 % 4.76 %
Grays Harbor 632 1.09 % 6.25 %
Mason 515 1.00 % 7.14 %
Other3 0 0.00 % 0.00 %
1

Not statistically significant between census tracts based on chi squared test: p = 0.28.

2

Not statistically significant between census tracts based on chi squared test: p = 0.28.

3

Other LHJs which had zero adult population living in pharmacy deserts were: Adams, Columbia, Garfield, Island, Jefferson, Kittitas, Lincoln, Pacific, San Juan, Skamania, Wahkiakum, Walla Walla, and Whitman.

About one-third (30 %; 432/1441) of all census tracts in Washington were considered “high” or “very high” risk for COVID-19 based on the CCVI. However, 67 % (85/127) of census tracts identified as pharmacy deserts in Washington were “high” or “very high” risk for COVID-19. Exhibit 2 depicts the pharmacy deserts by tract as orange for tracts that are pharmacy deserts and red for tracts that are both pharmacy deserts and “high” or “very high” COVID-19 risk. Location of pharmacies are noted as points in black on the map, and county boundaries are noted with thicker border lines than for tracts. Exhibit 3 provides the same map for King County, the most populous county in the state. An interactive HTML version of the map with additional data available is provided as Supplemental Material.

Exhibit 2.

Exhibit 2

Pharmacy desert communities in Washington state.

Exhibit 3.

Exhibit 3

Pharmacy desert communities in King County, Washington.

A slightly higher proportion of urban communities (9 %; 111/1232) were pharmacy deserts compared to rural (8 %; 16/208), though this difference was not statistically significant (p = 0.52). There were 38,678 adults living in rural pharmacy deserts and 415,364 adults living in urban pharmacy deserts. There were 111 urban pharmacy deserts out of 1232 urban tracts and 16 rural pharmacy deserts out of 209 rural tracts.

Pharmacies per capita

In examining pharmacies per adult population in Washington, 69 % (988/1441) of communities were considered healthcare shortage areas that had fewer than 1 pharmacy per 3,500 population. The mean number of pharmacies per 3,500 population in each county ranged from 0.37 in Skamania County to 2.0 in Garfield County. Of the 36 LHJs, 28 have a mean number of pharmacies per capita of less than 1 per 3,500 adult population. These data specific to LHJ are summarized in Exhibit 4.

Exhibit 4.

Pharmacies per population by local health jurisdiction.

Local Health Jurisdiction Pharmacies per 3500 Population Proportion of Adult Population Living in HPSA areas
Skamania 0.37 83.0 %
Klickitat 0.40 100.0 %
Island 0.47 84.1 %
Clark 0.66 71.9 %
Mason 0.68 68.1 %
Walla Walla 0.70 70.2 %
San Juan 0.72 63.1 %
Whatcom 0.73 63.1 %
Skagit 0.75 74.5 %
Pierce 0.76 70.4 %
Jefferson 0.77 67.9 %
Kitsap 0.77 71.3 %
Thurston 0.80 78.4 %
King 0.81 71.2 %
Snohomish 0.81 67.2 %
Benton-Franklin 0.81 69.6 %
Chelan-Douglas 0.82 74.0 %
Adams 0.83 56.2 %
Whitman 0.84 76.9 %
Clallam 0.84 69.9 %
Cowlitz 0.85 67.2 %
Lewis 0.86 67.5 %
Yakima 0.89 61.0 %
Grant 0.89 59.0 %
Kittitas 0.92 67.8 %
Northeast Tri County 0.94 75.5 %
Wahkiakum 0.98 100.0 %
Spokane 0.99 61.4 %
Grays Harbor 1.03 50.8 %
Columbia 1.09 0.0 %
Pacific 1.16 50.1 %
Okanogan 1.20 34.5 %
Lincoln 1.26 52.9 %
Asotin 1.37 68.3 %
Garfield 2.07 0.0 %
Note: HPSA (Health Provider Shortage Area) is defined as an area with less than one provider per 3,500 population.

Discussion

To our knowledge, this is the first study to define pharmacy deserts at the local level in Washington and to explore the relationship between community COVID-19 risk and pharmacy deserts. Most adults who live in pharmacy deserts are in King, Pierce, and Snohomish counties, the most populous counties in Washington State. These results also indicate that communities which have poor access to pharmacies are also often those at higher risk for COVID-19. The census tract-level granularity of these results provides state and local health departments with information about opportunities to work with community pharmacies to address outbreak prevention and mitigation, as well as where the state should mobilize additional healthcare resources for communities with the greatest inequities and COVID-19 risk. Longer-term, these data could provide information for pharmacies about their community’s health needs and opportunities to expand patient care services to increase healthcare equity.

Policy implications

Solutions or healthcare policy changes are needed to improve access to pharmacy-based patient care services and strengthen healthcare infrastructure in specific communities, especially for future public health emergency and pandemic preparedness. Several policy changes that could support a stronger pharmacy infrastructure that addresses the health inequities found in our study have been proposed and generally fall into three categories: 1) improve reimbursements, payment models, and financial incentives for practicing pharmacists to practice in underserved areas, 2) prevent closures of pharmacies, and 3) deploy innovative care delivery methods such as telehealth and mail-based services.

Policy solution 1: Expand pharmacist reimbursement. In April of 2021, the Pharmacy and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) was introduced to US Congress [32]. This act would grant pharmacists “provider status” and allow them to bill Medicare Part B for services that they regularly provide in underserved communities including medication management, point-of-care testing, immunizations, and chronic disease management [33]. Since 1987, the Centers for Medicare and Medicaid (CMS) has offered bonuses to healthcare providers in designated shortage areas, and these incentives were further expanded by the Affordable Care Act in 2011 with the goal to increase the supply of primary care services in specific underserved geographies [34], [35]. These policies were evaluated by the Department of Health and Human Services in 2015, which found that the financial incentives did indeed increase the number of providers in HPSAs, albeit only by a small amount (increase from mean of 6 to mean of 7 providers in HPSAs) [36]. Pharmacy deserts, by definition, are in low-income communities, and this analysis highlights that these communities are potentially also at higher risk for COVID-19. These communities are where gaps in access to care are the starkest and addressing these gaps will require financial support for pharmacies to feasibly provide services there. In 2015, Washington became the first state to grant pharmacists status as health care providers, including coupling that status with mandatory reimbursement for those essential health services [37]. This law allows patients to access covered medical benefits when provided in pharmacies, however the magnitude of the impact of this policy on patient access to services is yet to be fully evaluated and implementation barriers remain [37], [38], [39]. While Washington was the first state to enact a law granting pharmacists “provider status,” the Pharmacy and Medically Underserved Areas Enhancement Act still has important implications for Washington pharmacies because it would extend that “provider status” to cover Medicare services, which must be accomplished at the federal level. In states with broad pharmacist scope-of-practice regulations, such as Washington, pharmacies are not able to implement those services broadly while they remain unlinked with payments. A recent analysis by Murphy et al similarly concluded that “aligning the pharmacist business model to be comparable to other health care professionals will ensure patients receive access to pharmacist-provided cognitive patient care services.” [40] Granting pharmacists “provider status” nationally may alleviate some financial pressures in pharmacy deserts, however, until implemented, the extent of the impact of improved CMS reimbursements on pharmacy budgets remains to be seen.

Policy solution 2: Prevent closures of community pharmacies. A recent study found that 1 in 8 pharmacies closed between 2009 and 2015 nationally, with closures being disproportionately of independent pharmacies and of pharmacies in low-income communities [10]. Further, in November 2021, CVS, the second-largest pharmacy chain in the US, announced the upcoming closure of 900 of their community pharmacies over the next three years, which is approximately 1 in 10 of their stores [41], [42]. This is consistent with findings from a wide-ranging body literature on the nature of spatial distribution of health and community services; as one analysis stated: “the reasons behind pharmacy siting decisions are rooted primarily in market forces and are not based on need[s] of the community” [16]. Our results in this analysis found that out of the 36 local health jurisdictions in Washington, 28 of them have a mean number of pharmacies per capita that is less than one per 3,500 (the threshold definition of a Health Professional Shortage Area), and these pharmacy shortages occurred in both rural and urban areas of the state. In January 2022, House Bill 1813, “Concerning Freedom of Pharmacy Choice” was introduced to the Washington State Legislature, with the goal of expanding patient access to pharmacies not in their health insurance networks, including explicitly in pharmacy desert communities [43]. While improving CMS reimbursement and easing patient access restrictions may help alleviate some of the financial pressure on pharmacies, it will likely take additional policy, financial, or market-based incentives to keep brick-and-mortar pharmacies open, particularly in underserved communities.

Policy solution 3: Innovate on healthcare service delivery. In communities where local pharmacies have closed, pandemic preparedness and response services which might normally be based within a brick-and-mortar pharmacy are no longer available. Solutions to improve access to pharmacy services could also include innovations in care delivery through improved use of technology. For example, in the rural town of Shoshone, Idaho, that state’s first telehealth pharmacy opened which has sustained operations by using technology to reduce staffing costs while still providing pharmacist consultations for every prescription virtually and enabling residents to get their pharmacy needs without driving to a further city [44]. The sole remaining pharmacy in St. Charles Iowa, a town of 1,000 people, has adopted a similar model [45]. In Washington, the top three local health jurisdictions by proportion of population living in pharmacy deserts (Okanogan, Klickitat, and Benton-Franklin) are all highly rural communities, and potentially stand to benefit from innovative healthcare delivery models such as telehealth. This type of innovative model could have great potential for improving access to pharmacy-based services during a pandemic in other rural areas of the United States as well.

Strengths and limitations

Our study has notable strengths. Rather than calculating population within reach of a pharmacy by using only centroids of tracts, this analysis used block groups, which is the most granular level of geographic detail available in the ACS. This analysis also was able to capture populations living within reach of a pharmacy even if that pharmacy was in a neighboring tract, thus presenting a more accurate picture of the proportion of population in each tract is within reach of any pharmacy. This is also the first study to define pharmacy deserts at this level of detail in Washington, and the first study of any pharmacy deserts to examine the relationship of pharmacy deserts with associated COVID-19 risk.

We also note limitations to our study. We used linear distances to calculate geographic distance to pharmacies rather than travel time or road distance, and as such the number of people living in pharmacy deserts in this analysis is likely underestimated. The population of census block groups within each tract are assumed to be homogeneously distributed for the areal interpolation calculations of population within a certain radius of a pharmacy, which does not account for the existence of parks, non-residential buildings, and other spaces where people do not reside. In terms of data inputs, the 2019 ACS survey data are estimates of the population rather than actual counts, as opposed to the 2020 Decennial census data which are not yet available but could provide further precision to these population estimates. There are multiple limitations to the CCVI used in this analysis: 1) Though it is based on the widely-used SVI, since the CCVI itself is new since the start of the pandemic, it has not been as thoroughly validated as a measure of population-level health risk. However, the social and biological components underlying the COVID-19 measures of the CCVI have substantial evidence supporting them and the CCVI has been used by WADOH for other response planning efforts; 2) The risk indices underpinning the CCVI, namely the socioeconomic status sub-component, and the parameters comprising the pharmacy desert definition are highly correlated, which limits the validity of statistical inference about the relationship between the two variables. Due to lack of data availability in ACS and the CCVI, this analysis was unable to be conducted from the lens of the 29 sovereign tribal nations in Washington. Though WADOH and LHJs collaborate government-to-government with tribal officials for COVID-19 programs, the tribal nations have separate authorities and community health programs which were not in the scope of this analysis, though populations living in these tribal areas are included in the tract and county-level lens presented in our main analysis. Lastly, while there is limited generalizability of these results outside of Washington, these methods and publicly-available data can be straightforwardly applied to other states throughout the US.

While this analysis examines population-level access to pharmacies and risk with COVID-19, it should be noted that geographic access to pharmacies is not entirely synonymous with access to pharmacy-based services. Many prescription medications are delivered by mail, consultations can occur virtually through telemedicine, and COVID-19 testing and vaccination services are available at a variety of community and medical settings beyond pharmacies. While examining characteristics of specific pharmacy services or pharmacy operational characteristics (e.g., staffing) was not within the scope of this study, future studies could examine these components to further contextualize the relationship between pharmacy access and disease risk to obtain more precise estimates of gaps in care coverage during public health crises when healthcare resources are strained.

Conclusions

There are approximately 450,000 adults living in Washington communities that have low financial resources and poor geographic access to pharmacies. These “pharmacy desert” communities are more often associated with higher community-level risk of COVID-19 than communities that are not pharmacy deserts, and the results highlighted in this analysis can help provide local health jurisdictions with actionable location-based data to fill in these gaps in access to pharmacies. Longer-term, a combination of several policies and programs to address gaps in access to vital pharmacy-based services will be an important component of future pandemic preparedness and response, and broader equity in access to healthcare both in Washington and beyond.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was supported by the Elmer M. Plein Endowed Research Fund at the University of Washington School of Pharmacy, Seattle, WA.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jvacx.2022.100227.

Appendix A. Supplementary data

The following are the Supplementary data to this article:

Supplementary data 1
mmc1.zip (1.8MB, zip)

Data availability

Data will be made available on request.

References

  • 1.Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007–2015. PLoS One [Internet]. 2017 Aug 1 [cited 2020 Nov 5];12(8). Available from: /pmc/articles/PMC5559230/?report=abstract. [DOI] [PMC free article] [PubMed]
  • 2.Health and Human Services. Trump Administration Takes Action to Expand Access to COVID-19 Vaccines | HHS.gov [Internet]. [cited 2020 Oct 30]. Available from: https://www.hhs.gov/about/news/2020/09/09/trump-administration-takes-action-to-expand-access-to-covid-19-vaccines.html.
  • 3.Public Readiness and Emergency Preparedness Act [Internet]. [cited 2022 Jan 8]. Available from: https://aspr.hhs.gov/legal/PREPact/Pages/default.aspx.
  • 4.Strand M.A., Bratberg J., Eukel H., Hardy M., Williams C. Community pharmacists’ contributions to disease management during the COVID-19 pandemic. Prev Chronic Dis. 2020 Jul;23:17. doi: 10.5888/pcd17.200317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Aruru M, Truong HA, Clark S. Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals’ roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond [Internet]. Research in Social and Administrative Pharmacy. Elsevier Inc.; 2020 [cited 2020 Oct 30]. Available from: /pmc/articles/PMC7146711/?report=abstract. [DOI] [PMC free article] [PubMed]
  • 6.Cadogan C.A., Hughes C.M. On the frontline against COVID-19: Community pharmacists’ contribution during a public health crisis. Res Soc Adm Pharm. 2020 Mar 31 doi: 10.1016/j.sapharm.2020.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Qato DM, Daviglus ML, Wilder J, Lee T, Qato D, Lambert B. ‘Pharmacy Deserts’ Are Prevalent In Chicago’s Predominantly Minority Communities, Raising Medication Access Concerns. Health Aff [Internet]. 2014 Nov 2 [cited 2020 Oct 30];33(11):1958–65. Available from: http://www.healthaffairs.org/doi/10.1377/hlthaff.2013.1397. [DOI] [PubMed]
  • 8.Bach A, Goad J. The role of community pharmacy-based vaccination in the USA: current practice and future directions. Integr Pharm Res Pract [Internet]. 2015 Jul [cited 2020 Oct 30];4:67. Available from: /pmc/articles/PMC5741029/?report=abstract. [DOI] [PMC free article] [PubMed]
  • 9.Klepser N.S., Klepser D.G., Adams J.L., Adams A.J., Klepser M.E. Impact of COVID-19 on prevalence of community pharmacies as CLIA-Waived facilities. Res Soc Adm Pharm. 2021 Sep 1;17(9):1574–1578. doi: 10.1016/j.sapharm.2020.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Guadamuz J.S., Alexander G.C., Zenk S.N., Qato D.M. Assessment of Pharmacy Closures in the United States from 2009 Through 2015 [Internet] 2020 [cited 2021 May 4].;Vol. 180:157–160. doi: 10.1001/jamainternmed.2019.4588. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Qato D.M., Alexander G.C., Chakraborty A., Guadamuz J.S., Jackson J.W. Association between Pharmacy Closures and Adherence to Cardiovascular Medications among Older US Adults. JAMA Netw Open [Internet] 2019 doi: 10.1001/jamanetworkopen.2019.2606. https://jamanetwork.com/ Apr 1 [cited 2021 May 4];2(4):192606. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Neuner JM, Zhou Y, Fergestrom N, Winn A, Pezzin L, Laud PW, et al. Pharmacy deserts and patients with breast cancer receipt of influenza vaccines. J Am Pharm Assoc [Internet]. 2021 Nov 1 [cited 2022 Apr 11];61(6):e25–31. Available from: http://www.japha.org/article/S1544319121003071/fulltext. [DOI] [PMC free article] [PubMed]
  • 13.Pednekar P, Peterson A. Mapping pharmacy deserts and determining accessibility to community pharmacy services for elderly enrolled in a State Pharmaceutical Assistance Program. PLoS One [Internet]. 2018 Jun 1 [cited 2021 Mar 16];13(6). Available from: /pmc/articles/PMC5986116/. [DOI] [PMC free article] [PubMed]
  • 14.Wisseh C, Hildreth K, Marshall J, Tanner A, Bazargan M, Robinson P. Social Determinants of Pharmacy Deserts in Los Angeles County. J Racial Ethn Heal Disparities [Internet]. 2020 Oct 27 [cited 2020 Oct 30];1–11. Available from: http://link.springer.com/10.1007/s40615-020-00904-6. [DOI] [PMC free article] [PubMed]
  • 15.Ullrich F, Mueller K. Pharmacy Vaccination Service Availability in Nonmetropolitan Counties [Internet]. 2020 Dec [cited 2021 Jan 12]. Available from: http://www.public-health.uiowa.edu/ruprihttp://www.public-health.uiowa.edu/rupri/.
  • 16.Amstislavski P, Matthews A, Sheffield S, Maroko AR, Weedon J. Medication deserts: survey of neighborhood disparities in availability of prescription medications. Int J Health Geogr [Internet]. 2012 Nov 9 [cited 2021 Oct 24];11:48. Available from: /pmc/articles/PMC3517332/. [DOI] [PMC free article] [PubMed]
  • 17.Chisholm-Burns M.A., Spivey C.A., Gatwood J., Wiss A., Hohmeier K., Erickson S.R. Evaluation of racial and socioeconomic disparities in medication pricing and pharmacy access and services. Am J Heal Pharm [Internet] 2017 May 15 [cited 2021 Oct 24,;74(10):653–669. doi: 10.2146/ajhp150872. Available from: [DOI] [PubMed] [Google Scholar]
  • 18.Guadamuz J.S., Wilder J.R., Mouslim M.C., Zenk S.N., Alexander G.C., Qato D.M. Fewer pharmacies in black and hispanic/latino neighborhoods compared with white or diverse neighborhoods, 2007–15. Health Aff. 2021 May 1;40(5):802–811. doi: 10.1377/hlthaff.2020.01699. [DOI] [PubMed] [Google Scholar]
  • 19.Guadamuz JS, Alexander GC, Zenk SN, Kanter GP, Wilder JR, Qato DM. Access to pharmacies and pharmacy services in New York City, Los Angeles, Chicago, and Houston, 2015-2020. J Am Pharm Assoc [Internet]. 2021 Nov 1 [cited 2022 Apr 11];61(6):e32–41. Available from: http://www.japha.org/article/S1544319121003101/fulltext. [DOI] [PubMed]
  • 20.American Community Survey (ACS) [Internet]. [cited 2021 Sep 20]. Available from: https://www.census.gov/programs-surveys/acs.
  • 21.Rural Urban Commuting Area Codes - RUCA [Internet]. WWAMI Rural Health Research Center (RHRC). [cited 2021 Sep 20]. Available from: https://depts.washington.edu/uwruca/index.php.
  • 22.Community Vulnerability Index | COVID-19 | Surgo Foundation [Internet]. [cited 2020 Oct 30]. Available from: https://precisionforcovid.org/ccvi.
  • 23.COVID-19 Community Vulnerability Index (CCVI) Methodology - Google Docs [Internet]. [cited 2020 Oct 30]. Available from: https://docs.google.com/document/d/142EPwY0GqcSJlsD2fJOHIg_2G4e2ksxy8iToJ7maP4Y/edit.
  • 24.CDC/ATSDR’s Social Vulnerability Index (SVI) [Internet]. [cited 2021 Aug 9]. Available from: https://www.atsdr.cdc.gov/placeandhealth/svi/index.html.
  • 25.Local Health Departments :: Washington State Department of Health [Internet]. [cited 2020 Oct 30]. Available from: https://www.doh.wa.gov/AboutUs/PublicHealthSystem/LocalHealthJurisdictions.
  • 26.Wisseh C., Hildreth K., Marshall J., Tanner A., Bazargan M., Social R.P., et al. [cited 2021 Jan 11];1–11. Available from: 2020 Oct 27 doi: 10.1007/s40615-020-00904-6. [DOI] [Google Scholar]
  • 27.Pednekar P, Peterson A. Mapping pharmacy deserts and determining accessibility to community pharmacy services for elderly enrolled in a State Pharmaceutical Assistance Program. 2018 [cited 2020 Oct 30]; Available from: https://doi.org/10.1371/journal.pone.0198173. [DOI] [PMC free article] [PubMed]
  • 28.USDA ERS - Documentation [Internet]. United States Department of Agriculture - Economic Research Service. [cited 2021 Sep 20]. Available from: https://www.ers.usda.gov/data-products/food-access-research-atlas/documentation/.
  • 29.Liese A.D., Hibbert J.D., Ma X., Bell B.A., Battersby S.E. Where Are the Food Deserts? An Evaluation of Policy-Relevant Measures of Community Food Access in South Carolina. J Hunger Environ Nutr [Internet] 2014 [cited 2020 Oct 30,;9(1):16–32. doi: 10.1080/19320248.2013.873009. Available from: /pmc/articles/PMC4540074/?report=abstract. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Shah P.D., Trogdon J.G., Golden S.D., Golin C.E., Marciniak M.W., Brewer N.T. Impact of Pharmacists on Access to Vaccine Providers: A Geospatial Analysis. Milbank Q [Internet] 2018 Sep 1 [cited 2020 Nov 3,;96(3):568–592. doi: 10.1111/1468-0009.12342. Available from: /pmc/articles/PMC6131320/?report=abstract. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Berenbrok L.A., Gabriel N., Coley K.C., Hernandez I. Evaluation of Frequency of Encounters With Primary Care Physicians vs Visits to Community Pharmacies Among Medicare Beneficiaries. JAMA Netw Open [Internet] 2020 Jul 1 [cited 2022 Feb 23,;3(7):e209132–e. doi: 10.1001/jamanetworkopen.2020.9132. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2768247 Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.H.R.2759 - 117th Congress (2021-2022): Pharmacy and Medically Underserved Areas Enhancement Act [Internet]. H.R.2759 2021. Available from: https://www.congress.gov/bill/117th-congress/house-bill/2759/text.
  • 33.Fact Sheet: The Pharmacy and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) [Internet]. [cited 2021 Oct 24].
  • 34.Burney I.L., Schieber G.J., Blaxall M.O., Gabel J.R. Medicare and Medicaid Physician Payment Incentives. Health Care Financ Rev [Internet] 1979 [cited 2021 Oct 24];1(1):62. Available from: /pmc/articles/PMC4191066/ [PMC free article] [PubMed] [Google Scholar]
  • 35.Fact Sheet: Health Professional Shortage Area Physician Bonus Program [Internet]. 2021 [cited 2021 Oct 24]. Available from: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/HPSAfctsht.pdf.
  • 36.Health Practitioner Bonuses and Their Impact on the Availability and Utilization of Primary Care Services Final Report [Internet], US Department of Health and Human Services cited 2021 Oct 24. 2015. https://aspe.hhs.gov/sites/default/files/private/pdf/116816/FinalReport_HealthPractitionerBonuses_8_13_15%2520%2528v2%2529.pdf
  • 37.Hazlet T., Karwaki T., Downing D.F. Pathway to pharmacist medical provider status in Washington State [Internet] J Am Pharm Assoc. 2017:116–119. doi: 10.1016/j.japh.2016.09.003. Available from: [DOI] [PubMed] [Google Scholar]
  • 38.Guglielmo BJ, Sullivan SD. Pharmacists as health care providers: Lessons from California and Washington. J Am Coll Clin Pharm [Internet]. 2018 Oct 1 [cited 2021 Nov 22];1(1):39–44. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jac5.1035.
  • 39.Nguyen E., Walker K., Adams J.L., Wadsworth T., Robinson R. Reimbursement for pharmacist-provided health care services: A multistate review. J Am Pharm Assoc. 2021 Jan 1;61(1):27–32. doi: 10.1016/j.japh.2020.09.009. [DOI] [PubMed] [Google Scholar]
  • 40.Murphy EM, West L, Jindal N. Pharmacist provider status: Geoprocessing analysis of pharmacy locations, medically underserved areas, populations, and health professional shortage areas. J Am Pharm Assoc [Internet]. 2021 Nov 1 [cited 2022 Jan 22];61(6):651-660.e1. Available from: http://www.japha.org/article/S1544319121003629/fulltext. [DOI] [PubMed]
  • 41.CVS Health announces steps to accelerate omnichannel health strategy | CVS Health [Internet]. 2021 [cited 2021 Nov 22]. Available from: https://cvshealth.com/news-and-insights/press-releases/cvs-health-announces-steps-to-accelerate-omnichannel-health.
  • 42.U.S. National Pharmacy Market Summary. 2019 Jul.
  • 43.House Bill 1813 Concerning freedom of pharmacy choice [Internet]. State of Washington Jan 6, 2022. Available from: https://lawfilesext.leg.wa.gov/biennium/2021-22/Pdf/Bills/House Bills/1813.pdf?q=20220318123600.
  • 44.Wootton J. Telepharmacy Brings Meds to Rural Idaho Town [Internet]. 2017 [cited 2021 Oct 24]. Available from: https://www.hmpgloballearningnetwork.com/site/ihe/article/telepharmacy-brings-meds-rural-idaho-town.
  • 45.Hawryluk M. How Rural Communities Are Losing Their Pharmacies | Kaiser Health News. Kaiser Health News [Internet]. 2021 Nov 15 [cited 2021 Nov 22]; Available from: https://khn.org/news/article/last-drugstore-how-rural-communities-lose-independent-pharmacies/.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary data 1
mmc1.zip (1.8MB, zip)

Data Availability Statement

Data will be made available on request.


Articles from Vaccine: X are provided here courtesy of Elsevier

RESOURCES